Abstract. The Chinese herbal formula, Shu-Yu capsule (SYC), has been successfully used to treat depression-like disorders in clinical settings. To rapidly identify the chemical constituents of SYC and its metabolites in rat serum, a simple and sensitive liquid chromatography-tandem mass spectrometry method was established in the present study. By comparing the retention times, MS and MS n spectra data in the literature and reference standards, a total of 73 compounds were identified from SYC. In rat serum, 62 components, including 13 prototype compounds and 49 metabolites were identified. Of these components, 14 metabolites were confirmed as novel metabolites of SYC. The results of the present study indicated that certain flavonoid glycosides and monoterpene glycosides were absorbed directly. Glucuronidation and sulfation were identified as the predominant metabolic pathways of the components in SYC. In addition, certain phase I reactions, including hydrolysis, demethylation and hydroxylation occurred in the rats. These results provide scientific evidence, which support further investigations of the pharmacology and mechanism of SYC.
Introduction
The Shu-Yu capsule (SYC) formulation is a four-herb traditional Chinese medicine (TCM) used for the treatment of clinical depression-like disorders, including premenstrual syndrome (1) . It is composed of four herbal ingredients: Radix Bupleuri (Bupleurum chinense DC.), Radix Paeoniae Alba (Paeonia lactiflora Pall.), Rhizoma Cyperi (Cyperus rotundus Linn.) and Radix Glycyrrhizae (Glycyrrhiza uralensis Fisch.). According to the TCM formulation theory (2) , Radix Bupleuri and Radix Paeoniae Alba are mutually complementary as the monarch herbs of the formula, which represent the components with the major therapeutic roles.
It has been demonstrated that the total glycosides of peony exert significant antidepressant-like effects by increasing the expression levels of brain derived neurotrophic factor and nerve growth factor in selective brain tissues (3) . Radix Bupleuri is another monarch ingredient in SYC, which may affect the quality of prescriptions significantly. Bupleuri Radix, or prescriptions containing Bupleuri Radix as the major component, for example Xiaochaihutang, exert antidepressant-like effects by modulating serotonergic and noradrenergic systems in brain regions of rat models of depression (4, 5) . Our previous studies also revealed antidepressant-like effects of ethanol extracts from Paeonia lactiflora Radix and Bupleuri Radix (6) . These findings confirmed that Paeoniae Radix and Bupleuri Radix have effects on the central nervous system. According to the theory of serum pharmacochemistry, only constituents absorbed into blood have the potential to exert pharmacological bioactivities (7) . However, the metabolites absorbed in the blood following oral administration of SYC remain to be elucidated.
The present study aimed to confirm the absorbed components and the relative metabolites of SYC, which may be the potential bioactive components in the blood following intragastric administration of SYC. Thus, a reliable high performance liquid chromatography-electrospray ionization tandem mass 4 and HUI-YUN ZHANG spectrometry (HPLC-ESI-MS n ) system was established for the detection of prototype compounds and metabolites in the rat serum following oral administration of SYC. Screening for potential bioactive components in SYC may assist in future investigations into its mechanism of action at the molecular level.
Materials and methods
Reagents. Acetonitrile, methanol and glacial acetic acid were of LC/MS reagent grade and purchased from Merck Millipore (Darmstadt, Germany), Ultra-pure water was prepared using a Milli-Q water purification system (EMD Millipore, Bedford, MA, USA). The other solvents were of analytical grade.
Radix Bupleuri, Radix Paeoniae, Radix Glycyrrhizae and Rhizoma Cyperi were collected in Shandong Province (Shandong, China) and were authenticated by Professor Hui Yun Zhang (Shandong University of Traditional Chinese Medicine, Jinan, China). SYCs were manufactured by Qingdao Haichuan Innovative Biological & Natural Drug Research Institute (Qingdao, China).
The composition and preparation of the SYC were as previously described (1) .
Instrument and analysis conditions. The HPLC analysis was performed on an Agilent-1100 series liquid chromatograph system (Agilent Technologies, Inc., Santa Clara, CA, USA), equipped with a binary pump, an auto sampler, a photo-diode array detector and a column temperature controller. The analytical column was a Kromasil C18 100R (5 µm, 250x4.6 mm i.d.; AkzoNobel, Bohus, Sweden) and the oven temperature was maintained at 25˚C. A mobile phase, composed of eluent A (acetonitrile) and B (0.2% acetic acid in water, v/v) with a gradient was used for the separation. The elution conditions were applied with the following linear gradient: 0-5 min, 2-5% A; 5-12 min, 5-12% A; 12-28 min, 12-16% A; 28-42 min, 16-24% A; 42-56 min, 24-36% A; 56-72 min, 36-39% A; 72-81 min, 39-64% A; 81-90 min and 64-100% A. The flow rate was 1.0 ml/min and peaks were detected at 254 nm.
In the subsequent ESI-MS/MS experiment, an MSD Trap XCT Plus mass spectrometer (Agilent Technologies) was connected to the same HPLC instrument via an electrospray ionization (ESI) interface (Agilent Technologies, Inc.). The HPLC effluent was introduced into the ESI source in a post-column splitting ratio of 1:4. The ESI-MS operating conditions (negative ion) were optimized using the SYC, as follows: Nebulizer gas pressure, 40.00 psi; dry gas flow rate, 11.00 l/min; capillary temperature, 350˚C; electrospray voltage of the ion source, 3,500 V; skimmer of 40.0 V; capillary exit, 121.0 V; compound stability, 50%; trap drive level, 100%; target mass, 500 m/z; scan range, 100-14,00 m/z; collision energy, 1 V. A data-dependent program was used for the HPLC-ESI-MSn analysis, to enable the protonated or deprotonated ions to be selected for further MSn analysis. An Agilent 6300 Series Trap Control workstation (version 6.1; Agilent Technologies, Inc.) was used for data processing.
Preparation of samples for the extract. Sample preparation of the SYC was as follows: A single capsule from each of five batches of SYC were used. The powder-like contents of the capsules were mixed evenly, and 0.3 g of the mixed powder was weighed. The Radix Paeoniae, Radix Bupleuri, Rhizoma Cyperi and Radix Glycyrrhizae samples were crushed into a homogeneous size separately and sieved through a No. 40 mesh sieve (Jin Yuan Screen Factory, Yangquan, China) for further assessment.
The weighed powder was suspended in 25.0 ml of 70% (v/v) methanol and extracted in an ultrasonic water bath for 30 min at room temperature. Each resulting mixture was filtered through 0.22-µm membranes prior to use, and a 10-µl aliquot was injected into the HPLC-MS system for analysis.
In-vivo experiments.
A total of 24 male Wistar rats (weight, 180-220 g; age, 8 weeks) were supplied by the Laboratory Animal Center of Shandong University of Traditional Chinese Medicine. The present study was approved by the Institutional Committee for Animal Care and Use of Shandong University of Traditional Chinese Medicine. The rats were housed in poly cages with free access to food and water, at a temperature of 22-26˚C and relative humidity of 50-70%. The rats were acclimatized to the environment for 1 week prior to initiating the experiment. All rats were fasted, with free access to water, for 12 h prior to the experiment. Subsequently, 12 rats were administered with SYC at a dose of 4.1 g/kg body weight orally for 3 days, once per day. Another group of 12 rats served as a blank control group, which received physiological saline. On day 4, blood samples were collected from the inferior venae cava, 90 min after intragastric administration of SYC,and centrifuged at 1,500 x g for 15 min at 4˚C to obtain serum samples, which were then frozen and stored at -80˚C until analysis. Subsequently, the rats were sacrificed by cervical dislocation. The time points were selected based on our previous pharmacokinetic studies (8) . All procedures were in agreement with the National Institute of Health's Guidelines on the Principles of Animal Care (9) .
Sample preparation. The dried powders from the SYCs and the four herbs were weighed accurately (0.3 g), suspended in 25.0 ml of 70% (v/v) methanol, and extracted in an ultrasonic water bath (KQ-250E; Kunshan Ultrasonic Instruments Co., Ltd.) for 30 min at room temperature. Each resulting mixture was filtered through 0.22 µm polyvinylidene fluoride membranes (Merck Millipore) prior to use, and a 10 µl aliquot was injected into the HPLC-MS system for analysis.
Each collected serum sample was thawed and centrifuged at 1,500 x g for 30 min at 4˚C. The supernatant (100 µl) was then mixed with 300 µl methanol and vortexed for 2 min. The denatured protein precipitate was separated by centrifugation at 16,000 x g for 30 min at 4˚C, and the supernatant was separated and evaporated to dryness under a gentle nitrogen stream at 37˚C. The residue was reconstituted in 100 µl methanol and centrifuged at 16,000 x g for 30 min at 4˚C. An aliquot of 20 µl of the supernatant was analyzed on the HPLC-MS system.
Results

HPLC-MS
n analysis of constituents in SYC extract in negative ion mode. Utilizing the optimized LC-MS n method, the components of the extracts of SYC and its single herbal extracts (Radix Paeoniae Alba, Radix Bupleuri, Radix Glycyrrhizae and Rhizoma Cyperi) were identified. By comparing the MS n spectra data with the reference standards and literature data, 73 components, including flavonoids, terpenes and phenolic acids, were identified in the SYC extract. Among these 73 components, three predominant compounds were confirmed using reference standards. The HPLC-MS n data of the 73 tentatively identified components are summarized in Table I .
By comparing the chromatograms and MS n data between the extracts of SYC and the single herb extracts, the 73 identified components originated predominantly from Radix Bupleuri, Radix Paeoniae Alba and Radix Glycyrrhizae. In the SYC extracts, 34 compounds belonging to monoterpene glycosides, galloylglucoses and phenolic compounds were identified as being derived from Radix Paeoniae. In addition, 11 compounds belonging to flavonoids and triterpene glycosides were identified as ingredients of Radix Bupleuri, and 28 compounds were derived from Radix Glycyrrhizae. The identity of each component was confirmed by matching the empirical molecular formula with that of previously published information, and was further elucidated using multistage mass spectrometry, particularly for the unmatchable components in the in-house library. In addition, certain data, including retention time (tR), were also included as complementary data for identification. Acetic acid was added to the mobile phase as a modifier, and its adduct ions [M-H+CH 3 COOH] -were be observed in the mass spectra of certain components.
Identification of the components of SYC from Radix Paeoniae.
In the present study, a total of 34 compounds were identified in the extracts of SYC from Radix Paeoniae. For compound 16 (tR=24.7 min), the solvent adduct ion [M-H+CH 3 COOH] -at 539 m/z was observed, and the featured fragmentation ions at 283, 327, 357 and 479 m/z were produced, consistent with the data reported in the literature (10) . Compound 18 (tR=27.8 min) was identified as paeoniflorin by comparison with reference compounds, and produced the featured fragmentation ions at 165, 327 and 449 m/z, consistent with the data reported in the literature (10) . Compounds 19 (tR=28.7 min) and 27 (tR=36.5 min) were induced as an isomer of albiflorin and paeoniflorin, respectively, due to a series of common characteristic ions (Table I) . Compounds 32 (tR=45.3 min) and 33 (tR=45.7 min) were identified as isopaeoniflorin Compounds 53 (tR=57.5 min) and 55 (tR=58.4 min) were tentatively assigned as benzoylpaeoniflorin and isobenzoylpaeoniflorin (11) -were produced in negative ion mode. Compounds 19 and 20 were tentatively identified as tetragalloylglucose or an isomer. Similarly, compound 29 was tentatively deduced as pentagalloylglucose, according to the fragmentation pathway and data in the literature (17) . However, their structures were not elucidated from the MS data due to limited information regarding the linkage position of the galloyl groups relative to the glucose unit.
Compounds 8 (tR=15.8 min), 9 (tR=16.5 min), 34 (tR=46.1 min), 35 (tR=46.6 min) and 42 (tR=49.6 min) were detected and matched with the data in the literature (10), revealing that they were identical to those of isomaltopaeoniflorin sulfonate, paeoniflorin sulfonate, benzoylpaeoniflorin sulfonate or their isomers. A total of five saikosaponins (SSs) from the SYC extracts were identified or tentatively identified in the negative-ion ESI mode, among which two SSs, including SSa (compound 64; tR=71.9 min) and SSd (compound 65; tR=72. ) was its additional fragmentation ion. According to the common and additional fragmentation ions, compound 68 was tentatively deduced as prosaikogenin G or prosaikogenin F, and compound 69 was identified as prosaikogenin A or prosaikogenin D (19) . The structure of compound 68/69 and the possible fragmentation patterns are summarized in Fig. 1 . In addition, compounds 68 and 69 were possible secondary metabolites of the SSs in the plants during processing, storage or long-distance transport (20) . Identification of the absorbed components in rat serum following oral administration of SYC extracts. The absorbed components and metabolites were difficult to elucidate due to their low concentrations. In order to improve the detection sensitivity, extracted ion chromatograms (EICs) were used. First, the protonated molecular ions in Table I were used one by one to obtain EICs from the dosed rat serum, blank rat serum and SYC extract simultaneously. Subsequently, by comparing these obtained EICs, components that appeared in the dosed rat serum and SYC extract, but not in the blank rat serum, were considered to be the components absorbed into serum in the prototype. Once these components were determined as the absorbed components, they were further confirmed by carefully comparing their MS, MS n data and retention times with those in Table I . As a result, 13 prototype compounds were absorbed into the rat serum in the prototype and identified as quinic acid, desbenzoylpaeoniflorin, 6'-O-galloyldesbenzoylpaeoniflorin paeoniflorin sulfonate, albiflorin, paeoniflorin, liquiritin apioside, liquiritin, hydrated-liquiritin, galloylpaeoniflorin, galloylalbiflorin, apigenin-7-O-β-D-glucuronide and wogonoside.
Identification of the components of SYC derived from Radix
Identification of the components of SYC from Radix
Identification of the metabolites from rat serum following oral administration of SYC. Drug metabolism involves two types of enzyme-catalyzed reactions, phase I and phase II. Phase I metabolism includes oxidation, reduction, hydroxylation and desaturation; phase II metabolism includes glucuronidation, sulfation and glutathione conjugation, which may occur directly on the parent compounds, which contain appropriate structural motifs, or, as is usually the case, on functional groups added or exposed by phase I oxidation. These results increase the solubility of the drug metabolites in water, causing them to be more easily excreted from the body (27) . In the present study, sulfation, glucuronidation and methylation were detected as the predominant phase II reactions, and the oxidation reaction and demethylation were observed as the predominant phase I reactions. In general, 49 compounds were considered as metabolites of SYC (Table II) , in which 14 metabolites were confirmed as novel compounds.
Identification of gallic acid-associated metabolites.
In the present study, a total of 10 compounds were identified as metabolites of gallic acid or polyphenols, which can be degraded into gallic acid in the body. The possible metabolic pathways of gallic acid and the associated compounds are presented in Fig. 3 . M6 and M11 exhibited an [M-H] -ion at 233 m/z, which produced product ions at 189 and 153 m/z, suggesting that they were sulfate conjugates. Thus, M6 was determined as protocatechuic acid-4-sulfate, whereas M11 was identified as protocatechuic acid-3-sulfate, with reference to previous reports (15) . M12 exhibited the [M-H] -ion at 387 m/z and yielded product ions at 211, 197 and 175 m/z, indicating that M12 was a glucuronide conjugate of the three methylation products of gallic acid. M25 exhibited the [M-H] -ion at 297 m/z and the product ion at 121 m/z with a loss of 176 Da, indicating that M25 was the glucuronide conjugate of benzoic acid.
Identification of paeoniflorin-associated metabolites.
In the present study, a total of eight compounds detected in the rat serum were tentatively assigned as metabolites originating from paeoniflorin, which may also be the metabolites of other paeoniflorin-associated compounds, including desbenzoylpaeoniflorin or oxypaeoniflorin. With the exception of M5 (paeoniflorin sulfonate) and M9 (paeonimetabolinⅠglucuronide), the other six metabolites were identified for the first time as metabolites of paeoniflorin. The suggested metabolic pathways for paeoniflorin are shown in Fig. 4 Liquiritin was first metabolized into its aglycone liquiritigenin, and liquititigenin was then conjugated with glucuronide and sulfate. Isomerization into chalcones was also common for liquiritin. The present study revealed that M7, M17, M18, M31 and M32 were detected as major metabolites of liquiritin; and M20, M21, M38 and M35 were assigned as major metabolites of isoliquiritin. M17, M18, M20, M21 and M35 exhibited identical protonated molecules at 431 m/z, which produced identical product ions at 255, 135 and 119 m/z with a loss of 176 Da, indicating that they may be the glucuronide conjugates of liquiritigenin and isoliquiritigenin. However, the corresponding retention times differed markedly. According to the literature (23), the present study tentatively identified M17 and M18 as liquiritigenin-4'-O-glucuronide and liquiritigenin-7-O-glucuronide, respectively; and another three metabolites were identified as the glucuronide conjugates of isoliquiritigenin. Further investigation is required to determine the detailed structure of the metabolites of isoliquiritigenin. 3 spectrum, indicating that M48 may be the metabolite of the parent compound, quercetin. As a result, M48 was identified as dihydroxyl methyl quercetin-chalcone.
Identification of saponin-associated metabolites. M40 exhibited an [M-H]
-ion at 455 m/z, which produced a 
Identification of coumarin-associated metabolites. M41 produced a [M-H]
-ion at 559 m/z, which produced a product ion at 383 m/z with a loss of 176 Da, indicating that M41 was a glucuronide conjugate. In addition, the product ion at 383 m/z was 16 Da higher, compared with that of the molecular weight of glycycoumarin, which was tentatively assigned to hydroxylation reactions of glycycoumarin. Thus, M41 was identified as glycycoumarin hydroxylate glucuronide, which corroborates results from the literature (31) .
M49 yielded a [M-H] -ion at 447 m/z, which produced a product ion at 367 m/z with a loss of 80 Da (SO 3 ), indicating that M49 was a sulfate conjugate of glycycoumarin, according to the literature (31). Thus, M49 was tentatively identified as glycycoumarin sulfate.
Discussion
In the present study, an HPLC-ESI-MS n method was developed and applied to analyze the herbal components of SYC extracts, and the absorbed compounds and metabolites in rat serum following oral administration of SYC extracts. As a result, a total of 73 herbal components, including 28 monoterpenes, 26 flavonoids, 9 triterpenoids, 2 coumarins, and other phenolic compounds and galloyl glucoses were observed and tentatively identified. All the MS n data from these compounds in SYC were consistent with previous literature for every herb (10, 18) . The compounds identified from the formulation provided information to support further investigation on the absorbed components and metabolites of SYC in rat serum.
The absorbed components and metabolites identified in the present study provide an overall understanding of the absorption and metabolism of SYC in the rat body. Flavonoids were the most abundant metabolites in the drug-containing serum, and a total of 28 flavonoids, including five parent compounds and 23 metabolites, were identified in the drug-containing serum. Monoterpene glycoside compounds were found to be another primary absorbed component, including seven parent compounds and eight metabolites in the dosed serum were found. A total of eight metabolites were produced from gallic acid-related compounds and two metabolites were produced from the coumarin derivates. These results revealed that certain flavonoid glycosides and monoterpene glycosides were absorbed directly. Glucuronidation and sulfation were the predominant metabolic pathways of the components in SYC. In addition, it appeared that certain phase I reactions, including hydrolysis, demethylation and hydroxylation, also occurred.
Saponins are important in SYC, particularly the SSs, which were characterized with poor oral bioavailability. The majority of the SSs contained the unstable XIII, 28-oxide linkage, which may be hydrolyzed during extraction by organic acid or upon heating (32) . Therefore, SSs exert curative effects by sequential deglycosylation metabolism in the intestine to form secondary glycoside and aglycones with improved pharmacological effects.
As is already known, TCM contains complex chemical constituents, which are directly absorbed into the blood, or indirectly absorbed via digestive intake or liver metabolism, and are then transported to target tissue through the circulation and exert effects on target tissue. The complexity and diversity of parent compounds and metabolites in the serum following the administration of TCM conforms to the theory of integrity and the synergistic effect of TCM, which is the material basis of the pharmacological actions. However, further investigations are required to clarify such pharmacological actions.
A simple and economical HPLC-ESI-MS n method was established in the present study, and led to the first report, to the best of our knowledge, on the comprehensive determination of chemical constituents in SYC, as well as its metabolites in rat serum. The results of the present study provide a basis and theoretical foundation for clarification of the chemical composition and potential bioactive compounds of SYC. The results of the present study provided useful information for the further investigation of the pharmacology and mechanism of action of SYC.
